Clinical Trial Update: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II study of 5-FU, oxaliplatin plus dasatinib in metastatic pancreatic adenocarcinoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-FU (5-fluorouracil)
• DASATINIB (Dasatinib)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: University of Florida | Conditions: Pancreatic Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2019-06-13